Semaglutide Cost UK: NHS Prescription, Private Prices & How to Save Money

Semaglutide is available through the NHS in two licensed forms for different indications — understanding which applies to your situation is the first step to accessing it.

Ozempic (semaglutide, up to 2mg) — Type 2 diabetes: - Licensed for type 2 diabetes mellitus management - Prescribed by GPs and diabetologists where indicated by NICE diabetes guidelines (NG28 and related appraisals) - Available on standard NHS prescription - NHS prescription charge: £9.90 per item (2026), or free with a valid exemption certificate (e.g. diabetes exemption certificate — note: this applies to diabetes medications and is available to most type 2 diabetes patients on medication)

Wegovy (semaglutide 2.4mg) — Weight management: - Licensed for chronic weight management (BMI ≥35, or ≥30 with weight-related comorbidity) - Recommended by NICE TA875 for use within NHS specialist weight management services - Accessed via Tier 3 specialist weight management service referral, not general practice - NHS prescription charge: £9.90 per item, or free with PPC (Prepayment Certificate), income-based exemption, or other qualifying exemption - Important: Wegovy is NOT available on standard GP prescription for weight management — it requires specialist service referral and prescription

Prepayment Certificate (PPC): For patients on multiple regular medications, a PPC (currently approximately £111.60/year or £30.25/quarter) covers all NHS prescriptions regardless of number. If you pay for four or more prescriptions in three months, a PPC saves money.

*Prescription charges and exemption categories are subject to change. Confirm current charges with the NHS Business Services Authority (nhsbsa.nhs.uk).*

A common source of confusion for UK patients is the difference between Ozempic and Wegovy — they contain the same active ingredient (semaglutide) but are licensed for different purposes, come in different doses, and have different pricing.

Ozempic (semaglutide, up to 2mg): - Indication: Type 2 diabetes management - Doses available: 0.25mg, 0.5mg, 1mg, and 2mg weekly - Maximum dose: 2mg/week - UK list price (NHS indicative cost): approximately £73–£116 per pen (one pen = 4 weekly doses) depending on dose - On NHS prescription: patient pays standard charge (£9.90) or free with diabetes exemption

Wegovy (semaglutide 2.4mg): - Indication: Chronic weight management - Doses available: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg (escalation range) and maintenance at 2.4mg - Maximum dose: 2.4mg/week (higher than Ozempic's maximum) - UK list price: approximately £150–£280 per month depending on dose at private - On NHS prescription via Tier 3 service: patient pays standard charge (£9.90) or free with appropriate exemption

Key pricing insight: While Ozempic and Wegovy share the same active molecule, they are not interchangeable on prescription — a Wegovy prescription cannot be filled with Ozempic and vice versa. Using Ozempic off-label for weight loss (without type 2 diabetes diagnosis) is not appropriate NHS practice and can disrupt supply for patients who need Ozempic for diabetes management.

Supply considerations: Both Ozempic and Wegovy have experienced supply constraints in the UK. Check with your pharmacy before starting a course to confirm availability.

The private semaglutide (Wegovy) market in the UK has grown significantly since NICE approval. Several established providers offer varying pricing models, service levels, and access approaches.

Boots: - Online weight management service: Boots Health offers a Wegovy prescribing service via online or in-store consultation - Pricing: approximately £150–£250/month depending on dose - Includes online consultation and dispensing service - In-store collection or home delivery available - One of the most accessible options for patients who prefer a familiar high street brand

LloydsPharmacy Online Doctor: - Online prescribing service for Wegovy - Pricing: approximately £160–£270/month depending on dose - Online consultation with GMC-registered prescribers - Home delivery model

Manual (manual.co): - Men's health-focused platform that has expanded to weight management - Offers Wegovy and other weight management medications - Pricing: typically £139–£220/month — often competitive at lower dose levels - Subscription model includes clinical support

Numan: - Telehealth platform offering Wegovy via online consultation - Pricing: approximately £149–£249/month - Includes clinical monitoring and follow-up as part of subscription - Strong reputation for accessible telehealth delivery

General online pharmacy market: Additionally, numerous independent online pharmacies and telehealth services offer Wegovy — prices range from £140–£300/month. Always verify CQC registration and GMC-registered prescriber before using any service.

*All prices are approximate and subject to change. Always confirm current pricing directly with the provider.*

Compounded semaglutide — semaglutide prepared by a compounding pharmacy rather than the licensed manufacturer (Novo Nordisk) — has attracted significant attention in the UK, largely driven by supply shortages and lower pricing.

What is compounded semaglutide? Compounding pharmacies prepare medications from active pharmaceutical ingredients (APIs) for individual patients. Compounded semaglutide is essentially semaglutide prepared outside the licenced manufacturing process.

Regulatory status in the UK: - The MHRA has issued clear guidance: compounded semaglutide is not a licensed medicine in the UK - Compounding of semaglutide for weight loss purposes is not routinely lawful under UK medicines law, which requires specific clinical justification for each patient where no licensed alternative is available - Semaglutide IS available as a licensed product (Wegovy, Ozempic) — meaning the standard justification for compounding (no licensed equivalent available) does not apply - The MHRA has taken enforcement action against some suppliers

Quality and safety concerns: - Compounded products are not subject to the same quality, sterility, and potency controls as licensed medicines - Dosing accuracy of compounded formulations may be uncertain - Cases of underdosing and overdosing from compounded semaglutide have been documented - The MHRA has warned against purchasing compounded semaglutide from unverified sources

Our recommendation: UK patients should only use licensed Wegovy or Ozempic from registered UK pharmacies, dispensed against a valid prescription from a GMC or GPhC-registered prescriber. The modest cost saving from compounded alternatives does not justify the quality and safety risks.

*Regulatory guidance on compounded semaglutide may evolve. Check current MHRA guidance at gov.uk/mhra.*

Planning your semaglutide budget requires accounting for dose escalation, maintenance costs, consultation fees, and monitoring. The following provides a realistic annual cost framework for UK private patients.

Year 1 cost structure:

Months 1–4 (escalation phase — lower doses): - Average medication cost: approximately £120–£180/month (escalation doses are lower and cheaper) - Consultation fees: £0–£150 (one-off initial consultation for most services) - Approximate total: £480–£870 for months 1–4

Months 5–12 (2.4mg maintenance): - Average medication cost: approximately £180–£280/month - Monitoring/follow-up (included in most subscription services): £0 additional - Approximate total: £1,440–£2,240 for months 5–12

Total Year 1 cost estimate: approximately £1,920–£3,110

Year 2+ (maintenance): If continuing at 2.4mg maintenance: approximately £2,000–£3,200/year

Ways to reduce costs: - NHS access: If you meet criteria and can wait, NHS prescription is dramatically cheaper (£9.90/prescription or free) - Compare providers: Prices vary substantially — use our pharmacy comparison as a starting point - Check for promotions: First-month discounts are common among online providers - Consider Mounjaro: For some dose levels and providers, tirzepatide (Mounjaro) may be competitively priced vs Wegovy, with significantly greater efficacy

*All cost estimates are based on approximate 2026 UK market pricing and are subject to change. This is not financial advice.*